For clear cell renal cell carcinoma, gastric cancer, breast cancer and hepatocellular carcinoma (22–25), CXCL13 had good diagnostic and prognostic value, hence may become a candidate biomarker and therapeutic target. The gene discussed is CXCL13; the disease is breast carcinoma.